文献速递先天性心脏病外科心外重症与机械循环支持

儿童非扩张型心肌病的心脏移植等待与术后结局

Waitlist and Post-Heart Transplant Outcomes for Children With Nondilated Cardiomyopathy.
PubMed 文献 · Ann Thorac Surg · 2020-08-05

该研究基于儿科心脏移植等待名单数据,比较扩张型、肥厚型和限制型心肌病在三个时代的等待期与移植后生存。当前时代非扩张型患者VAD使用率低、UNOS 1A状态少、等待时间更长,但各表型等待与移植后生存相似,调整分析中VAD未增加等待期死亡。

要点

  • 当前时代肥厚型和限制型心肌病VAD使用率分别为2.7%和4.5%,远低于扩张型的23.4%。
  • 非扩张型患者UNOS 1A状态比例更低(39.8%和34.8% vs 75.6%),等待时间更长。
  • 调整分析中VAD使用未对非扩张型患者等待期生存产生不利影响。

核心结论

  • 当前时代所有心肌病表型的等待期和移植后生存相似。
  • 非扩张型心肌病患者VAD使用率低,但调整分析未增加等待期死亡率。

研究设计与样本

  • 回顾性队列研究,纳入1999年3月5日至2018年2月28日三个时代列名心脏移植的儿科心肌病患者。
  • 采用多变量Cox比例风险回归评估等待期和移植后生存。

主要发现

  • 当前时代扩张型、肥厚型、限制型心肌病的VAD使用率分别为23.4%、2.7%、4.5%。
  • 当前时代扩张型、肥厚型、限制型心肌病的UNOS 1A状态比例分别为75.6%、39.8%、34.8%。
  • 非扩张型患者等待时间更长(P < .01)。
  • 仅3.3%肥厚型和2.4%限制型心肌病患者植入VAD。
  • 肥厚型心肌病等待期生存和两种非扩张型心肌病移植后生存均显著改善。

临床怎么用

  • 当前时代非扩张型心肌病患儿等待期和移植后生存与扩张型相似,可参考相似管理策略。
  • 非扩张型心肌病VAD使用率低,但调整分析未显示增加等待期死亡,需个体化评估植入时机。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although outcomes for pediatric cardiomyopathy (CMP) patients have improved, an understanding of outcomes by CMP phenotype is essential. This study assessed changes in waitlist and post-transplant survival in nondilated cardiomyopathy (DCM) patients over 2 decades, explored ventricular assist device (VAD) utilization in this cohort, and identified risk factors for waitlist and posttransplant mortality in the current era. METHODS: Pediatric patients with a diagnosis of CMP listed for heart transplantation during three eras: Era 1: March 5, 1999 to December 31, 2004; Era 2: January 1, 2005 to December 15, 2011; and Era 3 (current era): December 16, 2011 to February 28, 2018 were included. Multivariable Cox proportional hazards regression was performed to assess waitlist and posttransplant survival. RESULTS: Compared with patients with DCM, those with hypertrophic and restrictive cardiomyopathy in the current era are less likely to be on VAD (23.4% vs 2.7% vs 4.5%); listed United Network for Organ Sharing Status 1A (75.6% vs 39.8% vs 34.8%), and more likely to have longer waitlist times (P < .01 for all). Only 3.3% hypertrophic and 2.4% restrictive cardiomyopathy patients had VAD implantation, although VAD use did not adversely impact waitlist survival in weighted non-DCM patients. Significant improvements have occurred in waitlist survival of hypertrophic and posttransplant survival of both types of non-DCM patients. CONCLUSIONS: Currently, waitlist and posttransplant survival is similar for all CMP phenotypes. VAD use is low in patients with non-DCM, although this did not increase waitlist mortality in adjusted analysis. Further studies in patients with non-DCM are needed to determine optimal timing and anatomic characteristics most likely to benefit from VAD implantation during the waitlist period.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Amdani S, Boyle G, Saarel EV, et al. Waitlist and Post-Heart Transplant Outcomes for Children With Nondilated Cardiomyopathy. Ann Thorac Surg. 2020. PMID: 32768427. doi:10.1016/j.athoracsur.2020.05.170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。